Adenosine deaminase activity in leukaemia

Smyth, John F.; Harrap, K. R.

doi:10.1038/bjc.1975.95

Cited by 101 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the marked increases of ADA activity in rapidly growing hepatomas (Fig. 3) anid in acute leukaemia cells (Smyth and Harrap, 1975;Meier et al, 1976) suggest that this enzyme may correlate with the process of malignant progression. A lack of correlation of ADA activity with cell proliferation per se seems to be indicated by the unchanged values in regenerating liver and neonatal liver.…”

Section: D)1scussionmentioning

confidence: 96%

“…Congenital deficiency of ADA is associated with the severe combined immunodeficiency syndrome (Giblett et al, 1972;Dissing and Knudsen, 1972;Parkman et al, 1975). In peripheral lymphoid cells from patients with chronic lymphocytic leukaemia, ADA levels were in the normal range (Scholar and Calabresi, 1973), but blast cells from patients with acute lymphoblastic leukaemia and acute myeloid leukaemia contained markedly higher ADA activity than normal peripheral leucocytes (Smyth and Harrap, 1975;Meier, Coleman and Hutton, 1976). Reid and Lewin (1957) found that ADA activity in a primary azo-dye-induced hepatoma was in the same range as in normal liver, and DeLamirande, Allard and Cantero (1958) showed that ADA specific activity in Novikoff hepatoma was twice that of normal rat liver.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Adenosine deaminase and adenosine kinase in rat hepatomas and kidney tumours

Jackson¹,

Morris²,

Weber³

1978

Br J Cancer

View full text Add to dashboard Cite

Summary.-Adenosine deaminase and adenosine kinase have been measured in rat liver, 12 transplantable hepatomas, regenerating, foetal and neonatal liver, adult and neonatal rat kidney and 2 transplantable kidney tumours. Adenosine deaminase activity, relative to the normal liver value, was elevated 2-4-fold in hepatomas of rapid growth rate, was in the normal range in more slowly growing hepatomas and in regenerating liver, and was low in foetal and neonatal liver. Adenosine kinase activity was decreased, relative to rat liver values, in all the hepatomas; activity of this enzyme gave a negative correlation with tumour growth rate. Kinetic properties of the two enzymes were examined in partially purified preparations. Adenosine deaminases from both liver and rapidly growing hepatoma 3924A were subject to weak product inhibition by inosine. Adenosine kinase from liver and hepatoma 3924A was inhibited by the reaction products ADP and AMP, and the enzyme was also subject to excess substrate inhibition by concentrations of ATP in excess of 1 mM. In rat hepatoma cell lines growing in culture, the toxicity of adenosine correlated inversely with the ratio of adenosine deaminase activity to adenosine kinase activity. Chromatographic measurements showed that hepatoma cells incorporated less extracellular adenosine into their adenine nucleotide pools than did isolated liver cells. These results indicate that increased adenosine deaminase activity and decreased adenosine kinase activity may confer a selective advantage upon the cancer cell.

show abstract

Section: D)1scussionmentioning

confidence: 96%

mentioning

confidence: 99%

Adenosine deaminase and adenosine kinase in rat hepatomas and kidney tumours

Jackson¹,

Morris²,

Weber³

1978

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Recently, the activity of the enzyme adenosine deaminase (ADA) has been shown to have specific importance for the metab-olism of lymphocytes (2). Tissue distribution studies show that ADA is usually present in all the tissues of the body with the highest activity in lymphocytes (3) and thymocytes (4). Furthermore, congenital absence ofthis enzyme, which arises as an inborn error ofmetabolism, results in the syndrome of severe combined immunodeficiency (5)(6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

Smyth¹,

Poplack²,

Holiman³

et al. 1978

J. Clin. Invest.

Self Cite

126

View full text Add to dashboard Cite

“…High values of ADA occur in the blast cells of patients with acute lymphocytic, acute myeloid, chronic mveloid and chronic myeloid blastic crisis leukaemia, (Smyth and Harrap, 1975). Because ADA was usually higher in lymphoblasts than myeloblasts, Smyth and Harrap postulated that measurement of ADA might be useful diagnostically in the undifferentiated acute leukaemias.…”

mentioning

confidence: 99%

Adenosine deaminase activity in peripheral blood cells of patients with haematological malignancies

Meier¹,

Colemán²,

Hutton³

1976

Br J Cancer

View full text Add to dashboard Cite

Summary.-Adenosine deaminase (EC 3.5.4.4, ADA) has been assayed in lymphocytes, granulocytes and erythrocytes from 45 patients with haematological malignancies. Activities were uniformly low in lymphocytes from patients with chronic lymphocytic leukaemia. Variable, but abnormal activities were frequently found in multiple myeloma, untreated lymphoma and leukaemic reticuloendotheliosis. High values were observed in lymphocytes from patients with lymphoma during intensive combination chemotherapy. ADA levels in lymphocytes were not correlated with levels in granulocytes or erythrocytes. ADA was elevated in blasts of patients with acute lymphocytic and myelogenous leukaemias but the ranges of activities per cell were so similar that ADA assay is unlikely to be of major help in distinguishing the two diseases.

show abstract

Adenosine deaminase activity in leukaemia

Cited by 101 publications

References 23 publications

Adenosine deaminase and adenosine kinase in rat hepatomas and kidney tumours

Adenosine deaminase and adenosine kinase in rat hepatomas and kidney tumours

Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

Adenosine deaminase activity in peripheral blood cells of patients with haematological malignancies

Contact Info

Product

Resources

About